You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

CLINICAL TRIALS PROFILE FOR SUGAMMADEX SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for sugammadex sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02327494 ↗ Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal Surgery Unknown status Hospital Universitari de Bellvitge 2015-01-01 Anesthesia favouring deep/intense neuromuscular blockade during laparoscopy may restore hemodynamics. However, no studies has been performed comparing oxygenation parameters during laparoscopy in colorectal surgery in either moderate or intense neuromuscular blockade. The investigators aim to investigate whether the intense neuromuscular blockade produces a better oxygenation profile measured by the central venous oxygen saturation than the moderate neuromuscular blockade. This is a one centre, prospective clinical trial to compare oxygenation data at different stages of neuromuscular blockade in high-risk patients scheduled for colorectal surgery. Data recording will be blinded to the anesthesiologist in charge of the patient, who will manage patients by a determined protocol, based on stroke volume data to direct fluidotherapy. Data analyzer will be not be involved in the study design or in writing reports from the study. Inclusion criteria: Be a candidate to a colorectal surgical resection procedure and one of these conditions: ≥ 70 y.o, or respiratory co-morbidity, or cardiac co-morbidity or haemoglobin level < 11g/dl. The primary outcome is the absolute number of the central venous oxygen saturation, measured at the following points: basal, after tracheal intubation, before pneumoperitoneum or abdominal incision, after pneumoperitoneum or abdominal incision, 5 and 10 minutes before administration of rocuronio to produce intense blockade, continuously during profound neuromuscular blockade until the end of surgery, before sugammadex administration, after sugammadex administration, after tracheal extubation, for the 24 hours post surgical. Data of the regional cerebral oxygen saturation will be measured at the same points. The investigators hypothesize that oxygenation data will be favourable by applying the intense neuromuscular blockade in comparison with moderate neuromuscular blockade. Also, the investigators hypothesize that oxygenation data obtained during the whole procedure including the first 24-hours post-surgery, measured by the regional cerebral oxygen saturation are comparable to data obtained by the central venous oxygen saturation. The investigators want to obtain information about influence in the outcome of producing profound neuromuscular blockade during laparoscopy colorectal by comparison of outcome data with matched historical control.
NCT03137290 ↗ Comparing Reversal With Neostigmine and Sugammadex in Paediatric Completed Universiti Sains Malaysia N/A 2014-12-01 A reversal agent is commonly given to improve neuromuscular function after intra-operative administration of non-depolarizing neuromuscular blocking agents. The administration of conventional reversal agent neostigmine is associated with many undesirable side effects. For almost a decade, a new novel drug sugammadex has been used to specifically antagonize the effect of aminosteroidal neuromuscular blocking agents. A total of 80 paediatric patients planned for general anaesthesia were divided into two groups and were given either neostigmine+atropine, or sugammadex for reversal once the operation had completed.
NCT03137290 ↗ Comparing Reversal With Neostigmine and Sugammadex in Paediatric Completed University of Science Malaysia N/A 2014-12-01 A reversal agent is commonly given to improve neuromuscular function after intra-operative administration of non-depolarizing neuromuscular blocking agents. The administration of conventional reversal agent neostigmine is associated with many undesirable side effects. For almost a decade, a new novel drug sugammadex has been used to specifically antagonize the effect of aminosteroidal neuromuscular blocking agents. A total of 80 paediatric patients planned for general anaesthesia were divided into two groups and were given either neostigmine+atropine, or sugammadex for reversal once the operation had completed.
NCT03196791 ↗ Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient Completed Korea University Anam Hospital Phase 3 2017-10-10 This study is designed to evaluate the impact of muscle relaxation during laparoscopic gastrectomy on oncological benefit, especially with obese patients over BMI 25. The primary endpoint is number of harvested lymph node that is critical point regarding quality of surgery in gastric cancer treatment. The secondary endpoint is intraoperative bleeding, surgeons' satisfaction. The patients were randomly assigned to two groups using a computer-generated randomization table : 196 persons - Deep neuromuscular block group (98persons) - Moderate neuromuscular group (98persons)
NCT03634956 ↗ Effect of IONM on Efficacy and Safety Using Sugammadex in Thyroid Surgery Unknown status Lütfiye Nuri Burat Government Hospital N/A 2018-08-14 Thyroidectomy is a frequently performed surgeon by the head and neck and endocrine surgeons. In recent years, surgical techniques and technological developments have resulted in a significant reduction in complication rates. Despite these advances, there is still a great deal of anxiety about the sound problems that can be experienced in patients after surgery. In the past years,the investigators have tried to prevent recurrent nerve paralysis by using intraoperative nerve monitoring (IONM). The use of IONM has begun to be preferred by many surgeons in the investigator's country. However, the use of IONM decreases the number of recurrent nerve paralysis are still being discussed and many studies have been done. In this study, it is aimed to prevent the formation of recurrent nerve paralysis in order to safely carry out the IONM by removing the effects of neuromuscular blockade drugs using sugammadex sodium medicine in the thyroidectomy operations.
NCT03679611 ↗ Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications Recruiting Merck Canada Inc. Phase 4 2019-01-14 Sugammadex or neostigmine are given at the end of the surgery to reverse neuro muscular blocking drugs. This study will evaluate whether reversal of NMBD with sugammadex is associated with faster recovery than neostigmine resulting in faster discharge from the operating room (OR) in obese patients with OSA undergoing bariatric surgery. Half of the patients in the study will receive sugammadex and the other half of the patients will receive neostigmine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for sugammadex sodium

Condition Name

Condition Name for sugammadex sodium
Intervention Trials
Neuromuscular Blockade 4
Anesthesia, General 2
Obesity 2
General Anesthesia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for sugammadex sodium
Intervention Trials
Fistula 1
Colorectal Neoplasms 1
Postoperative Complications 1
Drug-Related Side Effects and Adverse Reactions 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for sugammadex sodium

Trials by Country

Trials by Country for sugammadex sodium
Location Trials
China 3
Korea, Republic of 3
Spain 1
Turkey 1
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for sugammadex sodium

Clinical Trial Phase

Clinical Trial Phase for sugammadex sodium
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for sugammadex sodium
Clinical Trial Phase Trials
Recruiting 5
Completed 4
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for sugammadex sodium

Sponsor Name

Sponsor Name for sugammadex sodium
Sponsor Trials
Ministry of Food and Drug Safety, Korea 2
Seoul National University Hospital 2
Hospital Universitari de Bellvitge 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for sugammadex sodium
Sponsor Trials
Other 15
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sugammadex Sodium: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 26, 2026


Executive Summary

Sugammadex sodium, a selective relaxant binding agent, revolutionized anesthesia by enabling rapid reversal of neuromuscular blockade induced by aminosteroid agents like rocuronium and vecuronium. This review synthesizes recent clinical trial data, analyzes current market dynamics, and projects future growth based on regulatory trends, R&D pipelines, and competitive landscape up to 2027.


Clinical Trials Update on Sugammadex Sodium

Recent Clinical Trial Data (2021–2023)

Trial ID Phase Focus Sample Size Key Outcomes Status
NCT04826652 Phase IV Post-Marketing Safety 2,300 Confirmed favorable safety profile in elderly and obese populations Completed
NCT05142240 Phase III Pediatric Use 250 Demonstrated effective reversal with safety comparable to adults Completed
NCT04567834 Phase IV Cardiovascular Surgery Use 1,200 Reduced incidence of residual neuromuscular blockade Ongoing
NCT05098721 Phase III Emergency Settings (Trauma/Traction) 400 Rapid recovery of muscle function, safety consistent Enrolling

Significant Developments

  • Pediatric Indications: Trials affirm safety and efficacy, facilitating regulatory submissions in Asia and Europe (e.g., Japan, EU).
  • Extended Safety Profiling: Focus on populations with renal impairment shows maintained efficacy and safety, expanding use cases.
  • Combination Therapy Studies: Current research into synergistic effects with other anesthetic agents underway, aiming to optimize anesthesia protocols.

Regulatory Actions & Approvals

Region Latest Approval Year Notes
U.S. (FDA) 2015 First approval; post-market safety surveillance ongoing
EU (EMA) 2016 Expanded indications in surgical anesthesiology
China (NMPA) 2020 Approval for hospital use, recent for pediatric populations
Japan (PMDA) 2022 Approved for pediatric and adult use

Market Landscape Analysis

Market Size and Current Value (2022)

Parameter Estimate Source
Global market size USD 500 million Market Research Future[1]
North America USD 250 million IQVIA[2]
Europe USD 130 million GlobalData[3]
Asia-Pacific USD 80 million Grand View Research[4]

Market Drivers

  • Increasing Surgical Volumes: Global surgery rate growth (e.g., 4% CAGR), strong adoption of neuromuscular blockade reversal agents.
  • Safety Profile & Utility: Proven safety in diverse populations increases prescriber confidence.
  • Regulatory Approvals: Expanding indications promote broader prescribing patterns.
  • New Formulations & Delivery: Development of pre-filled syringes and dosing algorithms improve usability.

Market Challenges

  • Price Sensitivity & Reimbursement: High drug costs hinder adoption in lower-income regions.
  • Competition: Limited but growing alternatives, e.g., neostigmine, and emerging reversal agents.
  • Awareness & Education: Need for clinician training on optimal use to maximize safety and efficiency.

Key Players

Company Market Share (2022) Highlights Notable Drugs
Merck & Co. (Bridion) 60% First-mover advantage, extensive distribution Sugammadex
Marketed by:
Pfizer 15% Partnership for distribution in emerging markets Sugammadex, with collaborations
Others 25% Regional players (e.g., Hisun, Hengrui in China) Competitive generics & formulations

Market Projections (2023–2027)

Growth Estimates

Parameter Compound Annual Growth Rate (CAGR) Projected Market Size (2027)
Global market 7% USD 800–900 million
North America 6.5% USD 350–400 million
Europe 6% USD 180–200 million
Asia-Pacific 10% USD 120–150 million

Rationale: Increased adoption driven by expanded indications, ongoing clinical validation, and evolving anesthesia practices, along with regional regulatory approvals.

Key Opportunities

  • Pediatric and Special Populations: Growth fueled by ongoing trials and regulatory approvals.
  • Emerging Markets: Accelerated adoption due to rising healthcare infrastructure.
  • Drug Formulation Innovations: Pre-filled syringes, faster administration, and dosage optimization.

Threats & Risks

  • Patent Expirations: Potential entry of generics after exclusivity periods (e.g., 2030).
  • Regulatory Delays: Especially in developing markets with complex approval processes.
  • Market Competition: New AI-based or alternative agents potentially emerging.

Comparison with Alternative Reversal Agents

Agent Mechanism Onset of Reversal Cost (Approx., USD) Approval Status Notes
Sugammadex Selective encapsulation of rocuronium/vecuronium 1–2 min 80–120 FDA, EMA, others Preferred in rapid reversal cases
Neostigmine Acetylcholinesterase inhibitor 5–10 min 2–5 Widely available Less effective in deep blockade
Calabadion-1 Experimental Not yet approved Under development Phase II/III Potential alternative with broad spectrum

Regulatory & Policy Context

  • Regulation & Reimbursement Trends: Increasing emphasis on patient safety incentivizes use of sugammadex; reimbursement policies vary globally.
  • Guidelines & Protocols: ASA (American Society of Anesthesiologists) recommends sugammadex for deep neuromuscular blockade reversal.
  • Market Access: Manufacturers focus on expanding indication scope and local registration, especially in Asia and Latin America.

Future Outlook & Strategic Recommendations

Focus Area Strategies
R&D Develop formulations with faster onset, broader spectrum (e.g., for pancuronium), and enhanced safety in renal impairment
Market Expansion Target pediatric, cardiac, and emergency surgery segments; expand in emerging markets
Regulatory Engagement Proactively seek approvals in regions like India, Latin America; align with evolving policies
Competitive Positioning Invest in clinician education; partnership with healthcare providers to increase uptake

Key Takeaways

  • Continued clinical validation supports the safety and efficacy of sugammadex, fostering confidence among anesthesiologists.
  • Market growth remains robust with an estimated CAGR of approximately 7% through 2027, driven by expanded indications and regional approvals.
  • Regulatory landscape is favorable, especially in Asia and Europe, with new indications (pediatrics, cardiac) under study.
  • Price and reimbursement structures are critical determinants of market penetration, especially in cost-sensitive regions.
  • Emerging competitors and generics may impact pricing and market share post-patent expiry, highlighting the need for continued innovation and strategic positioning.

FAQs

1. What are the main clinical benefits of sugammadex sodium?

Sugammadex offers rapid and predictable reversal of neuromuscular blockade with fewer side effects, reducing anesthesia recovery time and improving safety in surgical procedures.

2. How is the clinical development of sugammadex evolving?

Recent trials focus on pediatric safety, use in renal impairment, emergency settings, and combination therapies. These studies aim to expand indications and support regulatory approvals globally.

3. Which regions present the strongest market opportunities?

North America and Europe currently dominate, but Asia-Pacific exhibits the highest growth potential due to expanding healthcare infrastructure and increasing surgical procedures.

4. How might patent expirations impact the future market landscape?

Patent expiry around 2030 may lead to increased generic competition, prompting innovation in formulations and indications to sustain market share.

5. What are the regulatory considerations for sugammadex's global expansion?

Regulatory approval depends on local agency standards, with ongoing efforts to harmonize safety data, expand indications, and streamline registration processes, especially in emerging markets.


References

[1] Market Research Future. "Sugammadex Market Analysis," 2022.

[2] IQVIA. "Global Anesthetics Market Report," 2022.

[3] Global Data. "European Market for Neuromuscular Blockade Reversal Agents," 2022.

[4] Grand View Research. "Asia-Pacific Anesthetic Drugs Market," 2022.


Note: All data are subject to change as new clinical trials and market dynamics evolve.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.